Improved precision of exposure-response relationships by optimal dose-selection. Examples from studies of receptor occupancy using PET and dose finding for neuropathic pain treatment
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605533881 | ||
| 003 | CHVBK | ||
| 005 | 20210128100840.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20150601xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s10928-015-9410-8 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s10928-015-9410-8 | ||
| 245 | 0 | 0 | |a Improved precision of exposure-response relationships by optimal dose-selection. Examples from studies of receptor occupancy using PET and dose finding for neuropathic pain treatment |h [Elektronische Daten] |c [Matts Kågedal, Mats Karlsson, Andrew Hooker] |
| 520 | 3 | |a An understanding of the relationship between drug exposure and response is a fundamental basis for any dosing recommendation. We investigate optimal dose-selection for two different types of studies, a receptor occupancy study assessed by positron emission tomography (PET) and a dose-finding study in neuropathic pain treatment. For the PET-study, an inhibitory E-max model describes the relationship between drug exposure and displacement of a radioligand from specific receptors in the brain. The model has a mechanistic basis in the law of mass action and the affinity parameter (Ki PL ) is of primary interest. For optimization of the neuropathic pain study, the model is empirical and the exposure response curve itself is of primary interest. An alternative parameterization of the sigmoid Emax model was therefore used where the plasma concentration corresponding to the minimum relevant efficacy was estimated as a parameter. Optimal design methodology was applied using the D-optimal criterion as well as the Ds-optimal criterion where parameters of interest were defined. For the PET-study it was shown that the precision of Ki PL can be improved by inclusion of brain regions with both high and low receptor density and that the need for high doses is reduced when a brain region with low receptor density is included in the analysis. In the case of the neuropathic pain study it was shown that a Ds-optimal study design using the reparameterized Emax model can improve the precision in the minimum effective dose compared to a D-optimal design. | |
| 540 | |a Springer Science+Business Media New York, 2015 | ||
| 690 | 7 | |a Dose finding |2 nationallicence | |
| 690 | 7 | |a Exposure response |2 nationallicence | |
| 690 | 7 | |a Optimal design |2 nationallicence | |
| 690 | 7 | |a PET |2 nationallicence | |
| 700 | 1 | |a Kågedal |D Matts |u Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden |4 aut | |
| 700 | 1 | |a Karlsson |D Mats |u Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden |4 aut | |
| 700 | 1 | |a Hooker |D Andrew |u Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden |4 aut | |
| 773 | 0 | |t Journal of Pharmacokinetics and Pharmacodynamics |d Springer US; http://www.springer-ny.com |g 42/3(2015-06-01), 211-224 |x 1567-567X |q 42:3<211 |1 2015 |2 42 |o 10928 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10928-015-9410-8 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s10928-015-9410-8 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Kågedal |D Matts |u Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Karlsson |D Mats |u Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Hooker |D Andrew |u Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t Journal of Pharmacokinetics and Pharmacodynamics |d Springer US; http://www.springer-ny.com |g 42/3(2015-06-01), 211-224 |x 1567-567X |q 42:3<211 |1 2015 |2 42 |o 10928 | ||